Menu Back to Drug-Induced-Injury-of-Liver-Heart-Kidney-and-Skin-Employing-Recent-Advances-to-Improve-Patient-Safety-and-Speed-Up-the-Pipeline

Program Committee

  • William W. Gregory, PhD
    William W. Gregory, PhD Senior Director, Worldwide Safety and Regulatory
    Pfizer Inc, United States
  • Pradip  Paul, MD, MS
    Pradip Paul, MD, MS Consultant
    Strategic Pharmacovigilance and Risk Management, United States
  • Scott H. Adler, MD
    Scott H. Adler, MD Senior Medical Director, Translational Patient Safety
    AstraZeneca Pharmaceuticals, United States
  • E. Stewart  Geary, MD
    E. Stewart Geary, MD Senior VP, Chief Medical Officer, Director, Corporate Medical Affairs HQ
    Eisai Co., Ltd., Japan
  • Michael  Merz, MD
    Michael Merz, MD Director, Discovery and Investigative Safety
    Novartis Institutes For Biomedical Research, Switzerland
  • Arie  Regev, MD
    Arie Regev, MD Head, Safety Advisory Hub, Chair Liver & GI Safety Comm, Global Patient Safety
    Eli Lilly and Company , United States
  • John R. Senior, MD
    John R. Senior, MD Associate Director for Science, Office of Surveillance and Epidemiology, CDER
    FDA, United States
  • Frank D. Sistare, PhD
    Frank D. Sistare, PhD Associate Vice President, Investigative Laboratory Sciences
    Merck & Co., Inc., United States
  • Norman  Stockbridge, MD, PhD
    Norman Stockbridge, MD, PhD Director, Division of Cardiovascular and Renal Products, OND, CDER
    FDA, United States
  • Stefan   Sultana, MD
    Stefan Sultana, MD Senior Medical Director, Companion Diagnostics
    Novartis Pharmaceuticals Corporation, United States
  • Aliza M. Thompson, MD
    Aliza M. Thompson, MD Clinical Team Leader, Division of Cardiovascular and Renal Products, OND, CDER
    FDA, United States
  • Paul B Watkins, MD
    Paul B Watkins, MD Professor; Director, Hamner-UNC Inst for Drug Safety Sciences
    University of North Carolina At Chapel Hill, United States
Load More

Digital Learning Catalog

eLearning Catalog Cover